AMR Bootcamp: What Makes a Good Project Succeed? ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 8-9 December 2021, Boston Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund and JPIAMR Moderators: Ursula Theuretzbacher, Center for Anti-Infective Agents Sumathi Nambiar, Johnson & Johnson Speakers: Lloyd Czaplewski, Chemical Biology Ventures Ltd David Melnick, Spero Therapeutics Subasree Srinivasan, Global Antibiotic R&D Partnership (GARDP) Introductions What is Needed to Build an Attractive Discovery and Preclinical Project? (Lloyd Czaplewski) How

Panel discussion: 'Choosing wisely — is your product worth developing?' JPIAMR Therapeutics Workshop 2021, 20-22 April 2021, virtual event Moderator: John Rex, F2G Ltd. Speakers: Kevin Outterson, CARB-X Laura Piddock, GARDP Camilla Petrycer Hansen, REPAIR Impact Fund Marco Cavaleri, EMA Christine Årdal, Representing IMI DRIVE-AB Jointly organized by:                    

Day 1 Introductory remarks Professor Laura J.V. Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) Session 1 - Keynote presentation Chair: Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) The politics of drug development Dame Sally Davies, UK Government Special Envoy on Antimicrobial Resistance, UK Department of Health and Social Care Session 2

Expert campus: 'Top 10 mistakes in antibacterial development' 4th AMR Conference, 24-28 August 2020, virtual event Moderator: Ursula Theuretzbacher, Founder, CEFAIA Speakers: Peter Warn, formerly SVP, Anti-infective Discovery, Evotec Richard Knight, Director & Co–founder, ApconiX Aleksander Danilovski, CSO & Senior Vice President Global R&D and Regulatory Affairs, Xellia Jointly organized by:                      

Antibiotic Bootcamps for Developers: Post-Approval Economics for New Antibiotics ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 3-6 September 2019, Boston Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust Moderator: Ryan Cirz Speakers: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and formerly Achaogen), Rolf Wagenaar (CD&E Consulting LLC, U.S.) Q&A session: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and

Antibiotic Bootcamps for Developers: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 3-6 September 2019, Boston Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund, JPIAMR and Wellcome Trust Moderator: Ursula Theuretzbacher (Center for Anti-Infective Agents, Austria) Speakers: Michael Mourez (Evotec, France), Douglas Huseby (University Uppsala, Sweden) Q&A session: Michael Mourez (Evotec, France), Douglas Huseby (University Uppsala, Sweden), Mariana Castanheira (JMI Laboratories, U.S.), Ursula Theuretzbacher (Center

Meet-the-experts session (S386): 'Enabling Academia to Fill the Discovery Gap ' ASM Microbe, 24 June 2019, San Francisco Learnings from Industry and Funders Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Bridging the Gap: NIAID Resources to Facilitate Discovery and Development of Anti-Infectives Robin Broughton, NIAID/NIH, Rockville, MD Find all details here to join us at this session! Jointly organized with:                  

BSAC Spring Conference 2019: Global views, local problems: Innovative solutions to AMR and infection challenges 21 – 22 March 2019, International Convention Centre, Birmingham, UK Parallel session one 'New initiatives to support AMR innovation' co-developed by GARDP and CARB-X Public health driven R&D of antibiotics for priority drug resistant infections Dr Seamus O'Brien, R&D Director, Global Antibiotic R&D Partnership (GARDP) CARB-X: Building A Portfolio of New Antibiotics, Vaccines & Diagnostics with Open Science Dr Richard

Pre-conference workshop: 'Resistance testing – beyond serial passage experiments' 12th Berlin Conference on Life Sciences - Novel Antimicrobials & AMR Diagnostics, 14-15 March 2019, Berlin Emergence of mutational resistance - Threat or myth? Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Testing of dual/multiple target drugs Michael Mourez, Evotec ID Lyon, France Testing of single target drugs Diarmaid Hughes, Uppsala University & ENABLE, Sweden Jointly organized with:                  

Antimicrobial Chemotherapy Conference 2019 - An ABC for Everyone Involved in Developing New Antimicrobials 15 January 2019, London Organized by the British Society for Antimicrobial Chemotherapy (BSAC) in collaboration with GARDP Session 1: Antimicrobial drug discovery - an essential overview Opening Remarks Laura Piddock, Head of Scientific Affairs, Global Antibiotic R&D Partnership (GARDP) The risks of clinical development from the perspective of the antibacterial discovery scientist David Shlaes, Former Professor of Medicine, Case Western Reserve University,

Antibiotic Bootcamps for Developers: Preclinical Toxicology ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 4-7 September 2018, Lisbon A collaborative project of GARDP and CARB-X Chair person: Ursula Theuretzbacher Speakers: Terry Miller, Claire Sadler, Ryan Cirz Roundtable discussion: Terry Miller, Claire Sadler, Ryan Cirz, Ursula Theuretzbacher Introduction Pitfalls in Preclinical Development from the Regulatory Perspective (FDA) (Terry Miller) Making Safety a Part of Drug Design (Claire Sadler) Real life story of unexpected toxicity - Lessons to

Antibiotic Bootcamps for Developers: Medicinal Chemistry ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 4-7 September 2018, Lisbon A collaborative project of GARDP and CARB-X Chair persons: John Griffin and Heinz Moser Speakers: Andrea Decker, Heinz Moser, John Griffin Roundtable discussion: Andrea Decker, Heinz Moser, John Griffin, John H. Rex Introduction Drug-Likeness: Physicochemical Properties in Small-Molecule Drug Discovery (Andrea Decker) Drug Discovery of Antibiotics: The Importance of Physicochemical Properties (Heinz Moser) Emerging Artificial Intelligence Approaches in

Meet-the-expert session ASM Microbe 2018, June 10, Atlanta Coping with Preclinical Toxicology Challenges Effective Use of Preclinical Toxicology to Advance Antimicrobial Drug Development: Insights from a Regulatory Expert Moderator: Ursula Theuretzbacher Speaker: Terry Miller Organized in collaboration with

John H. Rex Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed

William Hope Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

Sumathi Nambiar Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

Marco Cavaleri Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Lynn Silver, LL Silver Consulting, LLC Discussants:  Lynn Silver, LL Silver Consulting, LLC Tom Dougherty, Harvard Medical School John Tomayko, Infectious Diseases Consultant Sherman T. Waddell, Prokaryotics, Inc. Date : September 5th, 2017

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Tim Keutzer, Spero Therapeutics Discussants: Tim Keutzer, Spero Therapeutics Evan Hecker, Spero Therapeutics Mike Young, Tedor Pharma Inc Andrew Barlow, Syner-G Pharma Consulting Date : September 5th, 2017

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Judith Steenbergen, Paratek Pharmaceuticals Discussants: Erika Matuschek, EUCAST: Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Kevin Krause, Achaogen: NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Robin Patel, Mayo Clinic: Making Antibacterial Susceptibility Available in Clinical Practice Roundtable: Pitfalls in Development Date : September 5th, 2017